(CercleFinance.com) – Sandoz announces that it has signed an agreement to acquire the American ranibizumab biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences, for a payment of $170 million.
Cimerli is interchangeable with Lucentis for all indications in which the latter is approved. The transaction is expected to close during the first half of 2024, subject to customary conditions and approvals.
This acquisition will allow Sandoz to offer even more treatment options to US patients suffering from vision impairment or loss and to ‘build a more robust ophthalmic platform that would support future product launches’.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
This is a Smartvoice article: see legal notices